Moors & Cabot Inc. acquired a new position in Mesoblast Limited (NASDAQ:MESO) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 45,131 shares of the company’s stock, valued at approximately $67,000.
Several other hedge funds have also recently made changes to their positions in the company. Penbrook Management LLC boosted its holdings in Mesoblast by 0.7% in the 2nd quarter. Penbrook Management LLC now owns 248,150 shares of the company’s stock worth $1,856,000 after buying an additional 1,700 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in shares of Mesoblast in the first quarter worth about $1,794,000. Princeton Capital Management LLC grew its position in shares of Mesoblast by 1.0% during the first quarter. Princeton Capital Management LLC now owns 174,871 shares of the company’s stock worth $1,446,000 after purchasing an additional 1,658 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Mesoblast by 124.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 56,273 shares of the company’s stock valued at $465,000 after purchasing an additional 31,194 shares during the period. Finally, Morgan Stanley raised its stake in Mesoblast by 16.6% during the 1st quarter. Morgan Stanley now owns 51,715 shares of the company’s stock valued at $428,000 after purchasing an additional 7,369 shares during the period. Hedge funds and other institutional investors own 2.90% of the company’s stock.
Mesoblast stock opened at $5.99 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.57 and a quick ratio of 1.57. The firm has a market capitalization of $777.14 million, a P/E ratio of -7.30 and a beta of 3.40. Mesoblast Limited has a 1-year low of $5.83 and a 1-year high of $19.45. The company’s 50-day moving average is $6.93 and its 200 day moving average is $7.67.
Several equities research analysts have recently issued reports on MESO shares. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Mesoblast in a research report on Tuesday, August 31st. Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a report on Tuesday, August 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Friday, September 3rd. Chardan Capital decreased their price objective on Mesoblast from $7.50 to $6.50 and set a “sell” rating on the stock in a report on Tuesday, August 31st. Finally, Zacks Investment Research raised shares of Mesoblast from a “sell” rating to a “hold” rating in a report on Thursday, August 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $13.13.
Mesoblast Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.
Read More: Determine Your Level of Risk Tolerance
Want to see what other hedge funds are holding MESO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesoblast Limited (NASDAQ:MESO).
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.